论文部分内容阅读
目的：寻找能早期评估表浅膀胱癌术后行卡介苗（BCG）免疫治疗效果的精确指标。方法：分别采用CTLL－3H－TdR掺入法及夹心法酶联免疫吸附试验，测定32例表浅膀胱癌术后行BCG膀胱灌注者尿液中白细胞介素2（IL-2）及肿瘤坏死因子（TNF）含量。结果：全部病例均获随访26～67个月，平均43．5个月。32例中有6例复发（18．7％），复发患者灌注后尿液中IL－2及TNF含量分别为（14．34±6．83）u／ml及（78．63±37．45）ng／L，未复发患者IL-21、TNF含量分别为（21．41±9．23）u／ml及（106．76±49．13）ng／L，复发与未复发患者间IL－2、TNF水平比较均有显著性差异（分别P＜0．01和＜0．05）。结论：测定尿液中IL-2及TNF含量对判断表浅膀胱癌术后BCG灌注治疗的预后有重要的参考价值。
OBJECTIVE: To find out the precise indexes for evaluating the effect of BCG immunotherapy in early stage after superficial bladder cancer. Methods: CTLL-3H-TdR incorporation and sandwich enzyme-linked immunosorbent assay were used to detect the levels of interleukin 2 (IL-2) and tumor necrosis in urine of 32 patients with superficial bladder cancer after BCG bladder irrigation Factor (TNF) content. Results: All cases were followed up for 26 to 67 months with an average of 43.5 months. Six of 32 patients relapsed (18.7%). The levels of IL-2 and TNF in urine after reperfusion were (14.34 ± 6.83) u / ml and (78.63 ± 37.45 ), And the levels of IL-21 and TNF in non-recurrent patients were (21.41 ± 9.23) u / ml and (106.76 ± 49.13) ng / L, respectively. The levels of IL- 2, TNF levels were significantly different (P <0.01 and <0.05, respectively). Conclusion: The determination of urinary IL-2 and TNF levels in determining the prognosis of superficial bladder cancer after BCG infusion therapy has important reference value.